Prolonged‐Release Tacrolimus Is Less Susceptible to Interaction With the StrongCYP3A Inhibitor Voriconazole in Healthy Volunteers-Reference-Cited by-同舟云学术

Prolonged‐Release Tacrolimus Is Less Susceptible to Interaction With the StrongCYP3A Inhibitor Voriconazole in Healthy Volunteers

Published:2019-07-10 Issue:6 Volume:106 Page:1290-1298
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Huppertz Andrea¹,Ott Christian¹,Bruckner Thomas²,Foerster Kathrin I.¹,Burhenne Jürgen¹^ORCID,Weiss Johanna¹,Zorn Markus³,Haefeli Walter E.¹^ORCID,Czock David¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology and PharmacoepidemiologyUniversity of Heidelberg Heidelberg Germany

2. Department of Medical Biometry and InformaticsUniversity of Heidelberg Heidelberg Germany

3. Central LaboratoryUniversity Hospital Heidelberg Heidelberg Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1529

Reference50 articles.

1. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

2. THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2

3. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*

4. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug–drug interaction

5. Highly activated oral bioavailability of tacrolimus on coadministration of oral voriconazole

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort;Clinical Pharmacology in Drug Development;2024-01-04

2. The differences in drug disposition gene induction by rifampicin and rifabutin are unlikely due to different effects on important pregnane X receptor (NR1I2) splice variants;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-10-18

3. Tacrolimus—why pharmacokinetics matter in the clinic;Frontiers in Transplantation;2023-08-21

4. CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults;Clinical Pharmacokinetics;2023-07-28

5. Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles;Toxicology and Applied Pharmacology;2023-05